ImmuPharma (LON:IMM) Stock Price Down 15.3% - Here's Why

Key Points

• ImmuPharma's stock price fell 15.3% on Tuesday, trading as low as GBX 14.50 ($0.20) before closing at GBX 14.90.
• The company's market cap stands at £74.46 million, with a PE ratio of -1,674.16 and a negative return on equity of 131.41%.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, targeting lupus and potentially other conditions.

ImmuPharma plc (LON:IMM - Get Free Report) traded down 15.3% during mid-day trading on Tuesday . The stock traded as low as GBX 14.50 ($0.20) and last traded at GBX 14.90 ($0.20). 30,500,184 shares traded hands during trading, an increase of 263% from the average session volume of 8,394,409 shares. The stock had previously closed at GBX 17.60 ($0.24).

ImmuPharma Trading Up 5.7%

The company's 50 day moving average price is GBX 3.87 and its 200-day moving average price is GBX 3.15. The company has a market capitalization of £60.72 million, a PE ratio of -1,365.17 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.